| Identification | Back Directory | [Name]
Takinib | [CAS]
1111556-37-6 | [Synonyms]
Takinib
EDHS-206
Takinib >=98% (HPLC)
N-(1-Propyl-1H-benzo[d]imidazol-2-yl)isophthalamide
N1-(1-Propyl-1H-benzo[d]imidazol-2-yl)isophthalamide
3-N-(1-propylbenzimidazol-2-yl)benzene-1,3-dicarboxamide
1,3-Benzenedicarboxamide, N1-(1-propyl-1H-benzimidazol-2-yl)-
1-N-(1-propyl-1H-1,3-benzodiazol-2-yl)benzene-1,3-dicarboxamide | [Molecular Formula]
C18H18N4O2 | [MDL Number]
MFCD11822633 | [MOL File]
1111556-37-6.mol | [Molecular Weight]
322.36 |
| Chemical Properties | Back Directory | [density ]
1.30±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:30.0(Max Conc. mg/mL);93.06(Max Conc. mM) | [form ]
A solid | [pka]
12.13±0.43(Predicted) | [color ]
White to off-white | [SMILES]
CCCN1C2=CC=CC=C2N/C1=N\C(C3=CC(C(N)=O)=CC=C3)=O |
| Hazard Information | Back Directory | [Uses]
Takinib has been used as an inhibitor of transforming 28 growth factor - β-activated kinase -1 (TAK-1) in human leukemia monocytic THP-1 cells. It may be used as a TAK1 inhibitor in Jurk at cells. | [Biological Activity]
Takinib is a selective inhibitor of TAK1/MAP3K7 kinasewhich is a member of the MAP3K family and a key regulator of cell death. It binds in the TAk1 ATPbinding pocket with an IC50 value of 9.5 nM. Takinib selectively induced apoptosis following TNF-α stimulation in rheumatoid arthritis and breast cancer. | [in vivo]
Takinib (50 mg/kg; intraperitoneally; daily from days 18-36) reduces the clinical score in type II collagen-induced arthritis (CIA) mouse model of rheumatoid arthritis[4].
Takinib (50 mg/kg; oral gavage; daily until 17 days) slows tumor growth in the Hodgkin lymphoma xenograft NSG mice[5]. | Animal Model: | Male DBA/1 mice (CIA arthritis model)[4] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneally; daily from days 18-36 | | Result: | Showed a reduction in clinical arthritic score compared to vehicle control. |
| Animal Model: | Female NSG mice (8 weeks old)[5] | | Dosage: | 50 mg/kg | | Administration: | Oral gavage; daily until 17 days | | Result: | Slowed tumor growth and reduced tumor size/weight. |
| [IC 50]
TAK1: 9.5 nM (IC50); IRAK4: 120 nM (IC50); IRAK1: 390 nM (IC50); GCK: 430 nM (IC50); CLK2: 430 nM (IC50); MINK1: 1.9 μM (IC50) | [storage]
Store at -20°C |
|
|